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Ewing sarcoma (EWS) is the second most common bone and soft tissue-associated
malignancy in children and young adults. It is driven by the fusion oncogene EWS/FLI1
and characterized by rapid growth and early metastasis. We have previously discovered
that the mRNA binding protein IGF2BP3 constitutes an important biomarker for EWS
as high expression of IGF2BP3 in primary tumors predicts poor prognosis of EWS
patients. We additionally demonstrated that IGF2BP3 enhances anchorage-independent
growth and migration of EWS cells suggesting that IGF2BP3 might work as molecular
driver and predictor of EWS progression. The aim of this study was to further define
the role of IGF2BP3 in EWS progression. We demonstrated that high IGF2BP3 mRNA
expression levels correlated with EWS metastasis and disease progression in well-
characterized EWS tumor specimens. EWS tumors with high IGF2BP3 levels were
characterized by a specific gene signature enriched in chemokine-mediated signaling
pathways. We also discovered that IGF2BP3 regulated the expression of CXCR4 through
CD164. Significantly, CD164 and CXCR4 colocalized at the plasma membrane of EWS
cells upon CXCL12 stimulation. We further demonstrated that IGF2BP3, CD164, and
CXCR4 expression levels correlated in clinical samples and the IGF2BP3/CD164/CXCR4
signaling pathway promoted motility of EWS cells in response to CXCL12 and under
hypoxia conditions. The data presented identified CD164 and CXCR4 as novel IGF2BP3
downstream functional effectors indicating that the IGF2BP3/CD164/CXCR4 oncogenic
axis may work as critical modulator of EWS aggressiveness. In addition, IGF2BP3,
CD164, and CXCR4 expression levels may constitute a novel biomarker panel predictive
of EWS progression.
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INTRODUCTION
Ewing sarcoma (EWS) is a rare disease but it is still the
second most common malignancy of bone and soft-tissues
affecting pediatric age. It is characterized by a very aggressive
behavior, high propensity for metastasis, specifically to bone
and lung. Metastases occur in 30–40% of patients with
localized disease, while 20–25% of patients present metastasis
at diagnosis. The current standard treatment of EWS is a
multimodal approach consisting of surgery and/or radiotherapy,
and a multiagent chemotherapy, which confers a 5-years
survival rate of 70% in patients with localized tumor. On
the contrary, metastatic disease has a survival rate of 30%,
independently of intensification of chemotherapeutic regimens
(1). The identification of novel therapeutic strategies and reliable
predictors of patient survival is therefore imperative to improve
the outcome for metastatic patients.
While the genetic features of EWS are well-defined (2), as well
as the contribution of the fusion gene EWS-FLI1 to oncogenesis
(3), the molecular mechanisms underlying EWS metastases are
still poorly understood (4, 5).
EWS is characterized by one of the lowest mutation rates
among all tumors (6–8) and this genomic stability is conserved
in metastasis (9). On the contrary, epigenetic heterogeneity
is prevalent in EWS, and even increased in the metastatic
stage (10–12).
In general, EWS metastatic progression is regulated by
multifactorial mechanisms, which include the dynamic activation
of stress-adaptive or cellular plasticity pathways mediated
by epigenetic or post-transcriptional mechanisms (5, 13–16).
Previous reports have shown that EWS cells increase the
expression of genes associated with metastasis, such as CXCR4
or HIF-1α, through post-translational histone modifications or
RNA binding proteins (RBPs) activity (15, 17, 18). The G protein-
coupled receptor chemokine (C-X-C motif) receptor 4 (CXCR4),
activated by its natural ligand CXCL12, promotes migration of
EWS cells (13, 15).
RBPs, along with microRNAs and long non-coding RNAs,
represent major post-transcriptional regulators of gene
expression, due to their ability to bind RNA sequences and
finely tune nuclear export, translation/degradation rate, and
intracellular localization of their multiple transcript targets (19).
We have recently identified insulin-like growth factor 2
mRNA-binding protein 3 (IGF2BP3) as a major determinant
of EWS aggressiveness (20, 21). IGF2BP3 has a critical role
in modulating multiple mRNAs, thereby regulating tumor
initiation and progression (22). Accordingly, IGF2BP3 has
recently emerged as putative prognostic biomarker for several
tumors, including leukemia, carcinomas, and sarcomas (23).
In this study, we initially discovered that IGF2BP3 is
significantly upregulated in metastatic lesions of EWS patients
as compared to primary tumors, prompting us to investigate
the molecular contribution of this RBP to the migration and
dissemination of EWS cells. We then identified for the first time
an oncogenic axis consisting of IGF2BP3/CD164 and CXCR4,
which confers migratory advantage to EWS cells, particularly
under stress-adaptive conditions.
TABLE 1 | Clinical-pathological features of primary localized EWS patients
included in the study.
Characteristics qRT-PCR
(N = 48)
Microarray
(N = 29)
IHC
(N = 50)
No % No % No %
Gender Female 11 22.9 10 34.4 15 30
Male 37 77.1 19 65.5 35 70
Age ≤14 years 22 45.8 10 34.4 14 28
>14 years 26 54.2 19 65.6 36 72
Location Extremity 33 68.7 22 75.8 47 94
Central 4 8.3 2 6.9 3 6
Pelvis 11 23 5 17.2 0 0
Surgery YES 38 79.2 20 68.9 46 92
NO 10 20.8 9 31 4 8
Local Treatment RxT 10 20.8 9 31.0 4 8
RxT+Surgery 11 23 5 17.2 8 16
Surgery 27 56.2 15 51.7 38 76
Response to
chemotherapy*
Good 10 26.3 5 25 15 32.6
Poor 28 73.7 15 75 31 67.4
*Data available for 38 patients in qRT-PCR, for 20 patients in microarray and for 46 cases
in IHC.
qRT-PCR, quantitative Real-Time PCR; IHC, immunohistochemistry, RxT, radiotherapy,
EWS, Ewing sarcoma.
MATERIALS AND METHODS
Clinical Specimens
This study included EWS specimens from primary localized
tumors and EWS metastatic lesions. EWS diagnosis and
treatment were performed at the IRCCS Istituto Ortopedico
Rizzoli (Bologna, ITALY). For diagnosis, histological,
immunohistochemical, and molecular features were considered
(24). For therapy, patients underwent local treatment (surgery
and/or radiation therapy) and systemic induction chemotherapy.
All the patients included in this study were enrolled in previously
approved prospective studies (25, 26). For those patients who
underwent surgery, histologic response to chemotherapy was
examined in accordance to Picci et al. (27). Clinical-pathological
features of EWS patients, updated to 2018, are summarized in
Table 1.
Cell Lines
For in vitro studies, the following patient-derived EWS cell lines
were employed: A673 cells were provided by Dr. H. Kovar (St.
Anna Kinderkrebsforschung, Vienna Austria) while TC-71 cells
were provided by T.J. Triche (Children’s Hospital, Los Angeles,
CA). Cell lines authentication was executed by short tandem
repeat (STR) polymerase chain reaction (PCR) analysis using a
PowerPlex ESX Fast System kit (Promega, Madison, WI, USA)
and the last control was performed in December 2017. Absence
of mycoplasm contamination was assessed every 3 months using
MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland).
Stable silencing of IGF2BP3 was achieved using short hairpin
RNA (shRNA; TRCN0000074673) included in a pLKO.1 vector,
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and subsequent selection in puromycin (2µg/ml; Sigma, St.
Louis, MO, USA), as previously described (20, 21). Cell lines
were cultured as previously reported (28). For hypoxia studies,
cells were cultured in 1% O2 using a Galaxy 14S incubator (New
Brunswick, Eppendorf, Milano, ITALY) at 37◦C and 5% CO2.
Transient silencing of CD164 was performed using short
interfering RNA (siRNA) from GE Healthcare Dharmacon
(Lafayette, CO, USA); SMART POOL siGENOME_siRNA
(M-016196-00-0020). As control, siGENOME_non-targeting
siRNA was employed (D-001206-13-05). siRNAs (80 nM) were
transfected into EWS cells using TransIT-X2 (Mirus, Madison,
WI, USA) in accordance with the manufacturers’ protocol.
RNA-seq and Bioinformatics Analyses
RNA extraction, cDNA libraries, sequencing, reads alignment,
and normalization were performed as previously described
(21). Hierarchical supervised clustering was performed using
GeneSpring 11.02 software on differentially expressed genes
using Pearson’s correlation. Enrichment analysis of differentially
expressed genes was performed using MetaCore software
(GeneGo, Thomson Reuters).
Gene Expression Analysis
Extraction of total RNA from snap-frozen tissue samples, human
mesenchymal stem cell (hMSC) primary cultures, and EWS
cell lines was carried out using TRIzolTM Reagent (Invitrogen,
Carlsbad, CA, USA). Quantity and quality of obtained RNA were
measured by NanoDrop (NanoDrop ND1000, ThermoFisher
Scientific, Waltham, MA, USA) and/or by electrophoresis
analysis. Reverse transcription was performed using High
Capacity cDNA Reverse transcription kit (Applied Biosystems,
Foster City, CA, USA). Obtained cDNA was amplified by
quantitative Real-Time PCR (qRT-PCR) in a ViiATM 7
Real-Time PCR System (Applied Biosystems). Predesigned
TaqMan probe (Applied Biosystem) was employed for IGF2BP3
(Hs00559907_g1) expression level measurement. Primers
set for CD164 (Fw: 5′-GAGTGCTGTAGGATTAATTGGA
AAAT-3′, Rv: 5′-GGGAGGAATGGAATTCTGC-3′), CXCR4
(Fw:5′-ACGCCACCAACAGTCAGAG-3′, Rv: 5′-AGTCG
GGAATAGTCAGCAG-3′), and Nanog (Fw: 5′-CCTATGCCT
GTGATTTGTGG-3′, Rv: 5′-GATCCATGGAGGAAGGA
AGA-3′) were employed for SYBR green quantization. Primer
pairs for GAPDH, used as a reference gene, were employed as
reported previously (29). RT2 Profiler Cancer Inflammation and
Immunity Crosstalk PCR Array, profiling 84 genes involved in
those pathways, was purchased from Qiagen (Hilden, Germany).
Relative expression of analyzed transcripts was quantified
following the 2−11Ct method (30).
Immunohistochemistry
Paraffin-embedded EWS specimens were incorporated in tissue
microarrays (TMAs) and processed for immunohistochemistry
(IHC) using an avidin–biotin–peroxidase method (Vector
Laboratories, Inc., Burlingame, CA, USA). An overnight
incubation with the following primary antibodies was
performed: anti-CD164 (sc-271179, Santa Cruz Biotechnology,
Dallas, TX, USA) diluted 1:50, anti-CXCR4 (ab2074, Abcam,
Cambridge, UK) diluted 1:50, anti-IGF2BP3 (sc-47893, Santa
Cruz Biotechnology) diluted 1:50. Samples were classified as
follows: negative, when no staining was observed; positive when
weak, moderate, or strong staining was observed.
Western Blotting
For western blotting analysis, cells were harvested, rinsed with
PBS and lysed with ice-cold lysis buffer (50mM TrisHCl pH
= 7.4, 150mM NaCl, 1% Nonidet P-40 (NP-40), 0.25% sodium
deoxycholate, 1mM EGTA, 1mM sodium fluoride, protease,
and phosphatase inhibitors). Western blotting was performed
according to standard procedures. Membranes were incubated
overnight with the following primary antibodies: anti-IGF2BP3
(RN009P, dilution 1:20000, MBL International, Woburn, MA,
USA), anti-CXCR4 (ab124824, dilution 1:1000, Abcam), anti-
CD164 (AF5790, dilution 1:1000, R&D Systems, Minneapolis,
MN, USA), anti-HIF-1α (sc-10790, dilution 1:2000, Santa Cruz
Biotechnology), and anti-GAPDH (sc-25778, dilution 1:10000,
Santa Cruz Biotechnology). The following secondary antibodies
were used: anti-rabbit (NA934) and anti-mouse (NA9310V, GE
Healthcare, Little Chalfont, UK) or anti-sheep (HAF016, R&D
Systems) antibodies conjugated to horseradish peroxidase.
Motility Assay
Migration capability of EWS cells was established using
Trans-well chambers (CoStar, Cambridge, MA, USA). 1 ×
105 cells diluted in IMDM plus 1% FBS were seeded in
the upper compartment, whereas IMDM plus 1% FBS and
CXCL12 (100 ng/ml, ab9798, Abcam) were placed in the
lower compartment of the chamber. After an overnight
incubation, under normoxia or hypoxia, migrated cells were
fixed in methanol. Cells were subsequently stained with Giemsa
and counted.
Confocal Microscopy
Cells seeded on fibronectin-coated coverslips (Sigma) were
serum starved for 24 h and pretreated with 80µM dynasore
(S8047, Selleckchem, Houston, TX, USA), or DMSO as
control, in 1% FBS medium for 30min at 37◦C. Cells
were then stimulated with CXCL12 (100 ng/ml, Abcam) in
1% FBS medium for 5min at 37◦C. Cells were fixed in
4% paraformaldehyde, permeabilized in Triton X-100 0.15%-
PBS, blocked in 4% BSA and incubated with the following
primary antibodies: anti-CXCR4 (ab124824, dilution 1:100,
Abcam); anti-CD164 (sc-271179, dilution 1:50,Santa Cruz
Biotechnologies). Anti-rabbit rhodamine (#31686, dilution 1:100,
Thermo Scientific) and anti-mouse FITC (#31569, dilution 1:100,
Thermo Scientific) were employed as secondary antibodies.
Nuclei were counterstained with Hoechst 33256 (Sigma).
Confocal analysis was performed using Nikon A1R confocal
microscope with a Plan Apo 60x/NA 1.4 DIC N2 objective
(Nikon, Minato, Tokyo, JP). To determine colocalization of the
proteins of interest, Z-stacks were acquired at 0.25µm intervals
using the following settings: 1,024× 1,024 pixel, 2 scanner zoom,
0.5µm scan speed. Images were analyzed using Nis Elements
AR4.20.01 software (Nikon, Minato, Tokyo, JP). Colocalization
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was quantified by Mander’s Colocalization Coefficient as we
previously performed (31).
Ribo-Immunoprecipitation (RIP) Assay
The RiboCluster Profiler RIP-Assay kit (MBL International,
Woburn, MA, USA) was used to identify IGF2BP3/transcript
interactions, according to the manufacturers’ protocol.
For immunoprecipitation, anti-IGF2BP3 antibody (MBL
International) or normal IgG (MBL International), used as
a negative control, were used. Obtained RNA was reverse
transcribed and qRT-PCR on equivalent amounts of cDNA
was performed.
Statistical Methods
Differences among means were tested using a one-way
ANOVA, if more than two groups were present, or Student’s
t-test. Spearman’s rank test was employed to establish
correlation between continuous variables. Spearman’s
FIGURE 1 | Correlation between IGF2BP3 and metastatic disease in EWS patients. Scatter plot analysis of IGF2BP3 mRNA levels determined via (A,B) qRT-PCR or
(C,D) microarray (GSE12102) in primary or metastatic EWS lesions. Differential expression between the groups was determined using (A,C) Student’s t-test or (B,D)
one-way ANOVA with respect to metastases. Mean ± SD of relative mRNA expression reported as log2 is shown. Human mesenchymal stem cells were used as
calibrator. Number of analyzed cases is reported below each plot. *p < 0.05; **p < 0.01. NS, not significant.
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correlation coefficients (r) were defined as weak (0.1<
r < 0.39), moderate (0.4< r < 0.69), or strong (0.7<
r < 0.89), based on published definitions (32). Chi-
square test was employed to establish correlation between
categorized variables. Two-sided p < 0.05 was considered
statistically significant.
RESULTS
IGF2BP3 Is Associated With Metastasis
Formation and With Chemokine Signaling
To initially explore a possible correlation between
IGF2BP3 and EWS metastasis, we measured IGF2BP3
mRNA expression levels in 44 metastatic EWS lesions
using as controls 48 primary untreated tumors from
patients with localized disease at diagnosis (Table 1).
Metastatic specimens displayed significantly higher
expression of IGF2BP3 mRNA as evaluated by
qPCR (Figure 1A).
Notably, when the subset of primary tumors was divided
according to overall survival of patients (alive vs. dead from
disease), we found that the significant difference of IGF2BP3
mRNA expression levels was only maintained when compared
to tumors derived from patients with favorable overall outcome
(alive; Figure 1B). This observation was confirmed in a different
set of tumors previously analyzed by microarray analysis (29
primary tumors vs. 7 metastasis; Table 1) (9, 21). We did not
detect a significant difference in IGF2BP3 expression levels
between primary and metastatic tumors (Figure 1C). However,
IGF2BP3 expression levels were upregulated in metastatic lesions
as in primary tumors of patients dead from disease but they
were significantly lower in primary tumors of patients who did
not experience any recurrence or were alive at 10 years from
diagnosis (Figure 1D).
To further define whether IGF2BP3-regulated mechanisms
might have clinical impact, we took advantage of another set of
14 tumors analyzed by RNAseq (21). We compared the genetic
expression profile of three primary localized EWS cases with
the highest expression of IGF2BP3 to three primary localized
EWS cases with the lowest, if any, expression of IGF2BP3
and identified a signature of 814 differentially expressed
genes (615 upregulated and 199 downregulated, P < 0.05;
TABLE 2 | Enrichment analysis performed on 814 differentially expressed genes identified via RNAseq analyses in IGF2BP3-high vs. IGF2BP3-low expressers primary
localized EWS cases using GeneGo annotation.
# Pathway maps Total p-value FDR In data Network objects from active data
1 Immune response_ Antigen
presentation by MHC class I:
cross-presentation
99 4.4E−20 5.7E−17 30 IRAP, Rab-3B, Syk, Cathepsin L, HSP70, Dectin-1, Fc gamma RI, C1q, Fc epsilon RI
gamma, IP-30, TIM-3, Adipophilin, SREC-I, Cathepsin S, MSR1, MANR, FCGR3A,
Rab-35, DAP12, TLR4, Rab-32, OLR1, TLR7, CD74, Cathepsin B, TLR2,
gp91-phox, p67-phox, VAMP8, Fc gamma RII alpha
2 Chemokines in inflammation in
adipose tissue and liver in
obesity, type 2 diabetes and
metabolic syndrome X
48 1.3E−19 8.5E−17 22 ITGA4, ITGAX, ITGAM, ICAM1, IL-1 beta, CCL2, MIP-1-alpha, Fc gamma RI, PLAUR
(uPAR), MANR, IL-8, FCGR3A, MHC class II, VCAM1, TLR4, CD86, CD68, CXCR4,
CD163, CD45, TLR2, CD14
3 Macrophage and dendritic cell
phenotype shift in cancer
100 8.6E−14 3.7E−11 24 ITGAM, Activin A, PGE2R2, c-Rel (NF-kB subunit), IL-1 beta, EPAS1, PGE2R4, ILT4,
IDO1, DLL1, MSR1, MHC class II, WNT5A, M-CSF receptor, TLR4, TLR7, CD86,
GM-CSF receptor, Gas6, ILT3, IRF5, TLR2, SHIP, CSF1
4 Rheumatoid arthritis (general
schema)
50 7.6E−13 2.4E−10 17 IL-15, IL-18, ICAM1, MHC class II beta chain, IL-1 beta, Fc gamma RI, HLA-DRB,
TNF-R2, HLA-DRB1, FCGR3A, MHC class II, VCAM1, TLR4, CD86, TLR2, CD4,
CSF1
5 Neutrophil chemotaxis in asthma 38 1.4E−12 3.5E−10 15 C5aR, GRO-2, CCL2, MIP-1-alpha, HSP70, PI3K reg class IB (p101), IL-8, PTAFR,
GRO-3, CCR1, G-protein alpha-i family, GRO-1, TLR2, PI3K cat class IB
(p110-gamma), ENA-78
6 Immune response_ Antigen
presentation by MHC class II
118 4.1E−12 8.1E−10 24 MHC class II alpha chain, Syk, Cathepsin L, MHC class II beta chain, Dectin-1, Fc
gamma RII beta, Fc epsilon RI gamma, IP-30, HCLS1, Cathepsin S, MANR,
HLA-DM, Cathepsin V, FCGR3A, MYO1E, MHC class II, TLR4, CLEC10A, OLR1,
Legumain, CD74, TLR2, CD4, SWAP-70
7 Basophil migration in asthma 55 4.4E−12 8.1E−10 17 CCL18, ITGAM, C5aR, ICAM1, FPRL2, CCL2, MIP-1-alpha, PLAUR (uPAR), PI3K reg
class IB (p101), IL-8, CCR1, G-protein alpha-i family, VCAM1, GM-CSF receptor,
PLAU (UPA), PI3K cat class IB (p110-gamma), CCL13
8 Immune response_Alternative
complement pathway
53 2.9E−11 4.6E−09 16 C5aR, C3a, C3, C5 convertase (C3b2Bb), Factor I, Factor Ba, C3b, CRIg, Factor Bb,
C3aR, C3 convertase (C3bBb), iC3b, C3dg, Factor B, C3c, Clusterin
9 Maturation and migration of
dendritic cells in skin sensitization
41 7.8E−11 1.1E−08 14 MHC class II alpha chain, ICAM1, MHC class II beta chain, IL-1 beta,
MEKK1(MAP3K1), HLA-DRB, TNF-R2, HLA-DRB1, IL-8, HLA-DRB3, MHC class II,
HLA-DRA1, CD86, HLA-DRB5
10 Cell adhesion_Integrin inside-out
signaling in neutrophils
77 1.8E−10 2.3E−08 18 Syk, ICAM1, Fc gamma RI, Cytohesin1, PI3K reg class IB (p101), IL-8, PTAFR, Lyn,
Btk, DAP12, G-protein alpha-i family, Hck, GRO-1, Slp76, PI3K cat class IB
(p110-gamma), IP3 receptor, FYB1, PREL1
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FIGURE 2 | Characterization of the IGF2BP3/CD164/CXCR4 oncogenic axis in EWS cells. (A) qRT-PCR analysis performed with RT2 Profiler Cancer Inflammation
and Immunity Crosstalk PCR Array on IGF2BP3-depleted or empty vector-transfected (shCTR) A673 EWS cells. Data are shown as 2−11Ct using A673 shCTR as
calibrator and GAPDH as endogenous control. Mean ± SE of two independent experiments is shown. *p < 0.05, Student’s t-test. (B) CXCR4 expression analyzed via
(left) qRT-PCR or (right) western blot in IGF2BP3-depleted or empty vector-transfected (shCTR) A673 EWS cells. GAPDH was used as (left) housekeeping gene or
(right) loading control. Histogram and western blot represent the sum of three independent experiments. ***p < 0.001, Student’s t-test. (C) RIP assay performed on
extracts from A673 and TC-71 EWS cells using an IGF2BP3 antibody or non-immune isotype matched IgG. CD164 and Nanog mRNAs were quantified using
(Continued)
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FIGURE 2 | qRT-PCR analysis. Nanog was used as a negative control. Western blot shows the specificity of IGF2BP3 antibody. Histograms represent mean ± SE of
at least two independent experiments. **p < 0.01, Student’s t-test. (D) Western blot depicting CD164 expression on IGF2BP3-depleted or empty vector-transfected
(shCTR) A673 and TC-71 EWS cells. Representative western blots are shown. GAPDH was used as loading control.
one-way ANOVA; Supplementary Table 1). This signature
clearly separated the two groups with different IGF2BP3
expression levels when hierarchical supervised clustering was
performed (Supplementary Figure 1). Enrichment analysis
using GeneGo annotation revealed the specific involvement
of immunological and chemokine-mediated signaling
pathways (Table 2).
IGF2BP3 Regulates the Expression of
CXCR4 Through CD164
To confirm the functional association between IGF2BP3 and
chemokine signaling pathways, we took advantage of IGF2BP3-
depleted experimental EWS cell models previously generated by
shRNA approaches (21) (Supplementary Figure 2). We profiled
control-transfected and IGF2BP3-depleted A673 EWS cells for
genes encoding chemokine receptors and ligands using the RT2
Profiler Cancer Inflammation and Immunity Crosstalk PCR
Array. Notably, only CXCR4 was significantly downregulated
in IGF2BP3-depleted A673 cells compared to controls
(Figure 2A). Next, we confirmed by qRT-PCR and western
blotting analyses downregulation of CXCR4 at mRNA and
protein levels in IGF2BP3-silenced cells (Figure 2B), suggesting
that CXCR4 might work as novel downstream effectors of
IGF2BP3 action.
Data from the literature indicate that IGF2BP3 modulates the
expression of CD164 (33, 34), a type 1 integral transmembrane
sialomucin involved in the regulation of adhesion and migration
of tumor cells (35, 36). Significantly, CD164 regulates CXCR4
function in different tumor types (36–38). Thus, we initially
investigated a possible functional interaction between IGF2BP3
and CD164 mRNA by RIP assay. In both A673 and TC-
71 EWS cells CD164 was significantly enriched in samples
immunoprecipitated with anti-IGF2BP3 antibody as compared
to IgG-immunoprecipitated control samples (Figure 2C).
In addition, stable depletion of IGF2BP3 in A673 and TC-
71 cells (Supplementary Figure 2) was associated with a
significant reduction of CD164 protein expression levels
as demonstrated by immunoblot analysis (Figure 2D).
Next, we analyzed by qRT-PCR IGF2BP3, CD164, and
CXCR4 expression levels in clinical samples. We confirmed
statistical association among the three molecules in both
the 48 primary localized tumors and 44 metastatic lesions
previously described (Figures 3A–F). Because Spearman
coefficients (r) still indicated a weak to moderate correlation
between IGF2BP3 and CD164 or CXCR4 while a strong
correlation between CD164 and CXCR4 (32), we further
investigated the IGF2BP3/CD164/CXCR4 association by IHC
in an independent cohort of 50 primary tumors (Table 1).
The analyses confirmed a significant association at protein
level between CD164 expression with both IGF2BP3 (p =
0.05, Chi-square test) and CXCR4 (p = 0.04, Chi-square test)
(Table 3, Supplementary Figure 3).
Taken together these data support a role of IGF2BP3 in
regulating the CD164/CXCR4 complex and demonstrate the
evidence of an IGF3BP3-CD164-CXCR4 oncogenic axis critical
for EWS progression.
The IGF2BP3/CD164/CXCR4 Axis Affects
Migration of EWS Cells in Response to
CXCL12 and Under Hypoxia Conditions
While the role of CXCR4 in regulating migration of EWS cells
has been previously established (13, 15), there are no data
at the moment supporting the role of CD164 in modulating
EWS cancer cells motility. Thus, we used siRNA approaches
and transiently depleted CD164 in A673 and TC-71 cells.
We obtained a robust CD164 depletion in both cell lines
(Figure 4A), which determined a significant inhibition of EWS
cell motility in condition of chemotactic stimulus toward
a CXCL12 gradient (Figure 4B), supporting the notion that
CD164 might act as an adjuvant factor of CXCR4 signaling
in EWS cells.
We then investigated by confocal microscopy whether
CD164 and CXCR4 might colocalize in A673 cell line. In
CXCL12-unstimulated cells, a homogeneous distribution of
CD164 and CXCR4 was observed in the cytoplasm and
at the plasma membrane (Figures 5A,B). On the contrary,
upon CXCL12 stimulation, CD164 and CXCR4 colocalized
at the plasma membrane. To confirm that CD164 and
CXCR4 indeed interacts at the plasma membrane, we repeated
colocalization experiments supplementing CXCL12 with the
general endocytosis inhibitor dynasore, a GTPase inhibitor that
blocks dynamin activity, thus affecting both clathrin-dependent
and -independent endocytic pathways (39). The combination
of CXCL12 and dynasore enhanced colocalization of CD164
and CXCR4 (Figures 5A,B), confirming that this interaction
likely occurs at the plasma membrane of A673 cells (Figure 5A,
white arrows). Collectively these results suggest that CD164 and
CXCR4 colocalize at the plasma membrane of A673 cells in
CXCL12-dependent fashion.
Because CXCR4 is induced in EWS cells exposed to
hypoxia (13), a common condition of human tumor
microenvironment (40), we investigated the contribution
of the IGF2BP3/CD164/CXCR4 axis on CXCL12-evoked
biological responses of EWS cells under normoxic (21% O2)
or hypoxic conditions (1% O2). In line with previous evidence
(13), EWS cells exposed to hypoxia showed induced expression
of CXCR4 and of the hypoxia inducible factor alpha (HIF-1α),
used as control (Figure 6A). Interestingly, IGF2BP3-silenced
cells did not show CXCR4 expression, which was not increased
under hypoxic conditions (Figure 6A). From the functional
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FIGURE 3 | Analysis and correlation of IGF2BP3, CD164, and CXCR4 mRNA levels in EWS patients. Scatter plots displaying correlations between IGF2BP3, CD164,
and CXCR4 mRNA levels in EWS (A,C,E) primary tumors and (B,D,F) metastatic lesions analyzed via qRT-PCR. Number of analyzed cases is reported above each
column. Relative mRNA expression reported as log2 is shown. Human mesenchymal stem cells were used as calibrator. Correlation coefficient (r) and p-value were
calculated using Spearman’s rank test.
standpoint, the inhibitory effect on cell migration associated with
IGF2BP3 depletion was amplified under hypoxic conditions.
In fact, A673 cells silenced for IGF2BP3 showed reduced
migration in response to CXCL12 either in normoxic or
under hypoxia conditions (Figure 6B). Of note, the reduction
was more evident in hypoxia condition (p = 0.005, one-way
ANOVA), indicating that the impact of reduced expression
of the IGF2BP3/CD164/CXCR4 oncogenic pathway may
be stronger in the tumor microenvironment compared to
physiological conditions.
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DISCUSSION
EWS is characterized by a very low somatic mutational load (6–8)
and high levels of inter- and intratumor epigenetic heterogeneity
(10–12). Analysis of DNA methylation has highlighted a large
spectrum of alterations, which reflect disease heterogeneity in
term of stem cell differentiation and clinical outcome, and
preclude the possibility of identifying subset of patients with
differential risk of progression (12). Treatment of EWS is still
based on high dense chemotherapy, with relevant impact on
quality of life of survivors, who may be overtreated, and on
outcome of high-risk patients, who should be considered for
alternative drug regimens.
We have recently demonstrated that the mRNA binding
protein IGF2BP3 constitutes an important biomarker for EWS
(20, 21) as in fact high expression of IGF2BP3 in primary
tumors is associated with poor prognosis of EWS patients
(21). In addition, we demonstrated that IGF2BP3 increases
anchorage-independent growth and migration of EWS cells
(21) suggesting a putative role for IGF2BP3 as molecular
driver of EWS progression. In this study, we demonstrated
that: (A) High IGF2BP3 mRNA expression levels correlate
with EWS metastasis. (B) EWS tumors with high IGF2BP3
mRNA expression levels are characterized by a specific gene
signature enriched in chemokine-mediated signaling pathways.
(C) IGF2BP3 regulates the expression of CXCR4 through CD164.
(D) CD164 and CXCR4 colocalize at the plasma membrane of
EWS cells upon CXCL12 stimulation. (E) IGF2BP3, CD164, and
TABLE 3 | Association between CD164, CXCR4, and IGF2BP3 according to
Chi-square test in 50 primary localized EWS cases analyzed by IHC.
CD164 Negative Positive p-value
CXCR4 0.04
Negative 5 7
Positive 5 30
IGF2BP3 0.05
Negative 6 7
Positive 7 30
CXCR4, not evaluable in three cases.
CXCR4 expression levels correlate in clinical samples. (F) The
IGF2BP3/CD164/CXCR4 oncogenic axis promotes motility of
EWS cells in response to CXCL12 and under hypoxia conditions.
Previously published data from our laboratory indicates that
IGF2BP3 may exert its oncogenic action in EWS in both IGFs-
dependent and -independent manner. IGF2BP3 loss promoted
IGF1R downregulation and inhibited IGF1-evoked biological
responses, thereby reducing cell growth andmotility of EWS cells
(20). IGF1R loss was associated with a compensatory mechanism
driven by activation of the insulin receptor isoform A (IR-A) and
its cognate ligand IGF2, which conferred enhanced sensitivity
to dual IGF1R/IR inhibitors (20). On the other hand, IGF2BP3
expression is predictive of poor prognosis of EWS and regulate
EWS aggressiveness independently of IGF1R action (21). The
data presented here support the novel observation that in EWS
cells IGF2BP3 might be a critical factor in regulating a specific
cytokine pathway consisting of CD164 and CXCR4 signaling.
A role for CXCR4 in EWS has been previously demonstrated
(13, 15, 41). Expression of CXCR4 is highly dynamic in EWS, and
can be transiently induced by exposure to microenvironmental
stress, like starvation, growth constraint and hypoxia (13).
EWS cells characterized by high CXCR4 expression levels show
increased invasion and migration capability, partially mediated
by the intracellular activation of the Rho-GTPases, Rac1, and
Cdc42 (13). Significantly, targeting the CXCL12/CXCR4 axis
inhibited the aggressive phenotype, thereby indicating a potential
contribution of CXCR4 signaling to EWS metastasis (13).
In addition, in the model presented by Krook et al. stress
induces the conversion of CXCR4-negative EWS cells to CXCR4-
positive cells, thereby supporting the role of the CXCL12/CXCR4
signaling pathway in tumor progression (15). This switch is
mediated, at least in part, by epigenetic modifications of the
CXCR4 promoter, which transitions from an inactive bivalent
state to a univalent active state (15).
The adhesion receptor CD164 (endolyn), belonging to the
sialomucin family, regulates the adhesion of CD34+ cells to
bone marrow stroma, and the recruitment of those cells into
cycle (37). CD164 associates with CXCR4 and cooperates
with it in promoting CXCL12-mediated cell migration (37).
CD164 depletion significantly attenuated the PI3K pathway
but it did not alter MAPK activation, suggesting pathway
FIGURE 4 | Functional relevance of CD164 in EWS cells. (A) CD164 silencing was achieved in A673 and TC-71 EWS cells after 72 h of transfection of siCD164
(80 nM) or scrambled control siRNA (SCR; 80 nM). GAPDH was used as the loading control. (B) Histogram shows the migration of A673 and TC-71 cells treated with
siRNA or SCR using a CXCL12 (100 ng/ml) gradient. Mean ± SE of at least two independent experiments is shown. *p < 0.05; ***p < 0.001, Student’s t-test.
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FIGURE 5 | CD164 and CXCR4 colocalize upon CXCL12 stimulation in EWS cells. (A) Colocalization of CD164 and CXCR4 was assessed in A673 cells by
immunostaining and confocal microscopy. Cells were pretreated with dynasore (80µM), or DMSO as control, and then stimulated with CXCL12 100 ng/ml for 5min
(Time = 5min), or left unstimulated (Time = 0). Images were taken using confocal microscopy and representative single Z-stack pictures are shown (scale bar 25µm).
(B) Z-stacks were analyzed for colocalization by NIS Elements AR4.20.01 software (Nikon). Colocalization index is represented by histograms. Mean ± SE of an
average of 30 independent fields is shown. ns, not significant; ***p < 0.01; ****p < 0.0001, one-way ANOVA.
specificity of CD164 action (37). A tumorigenic role of CD164
has been demonstrated in ovarian cancer where CD164
is upregulated in malignant ovarian cancer cell lines (38).
CD164 overexpression in human ovarian epithelial surface
cells increased CXCL12/CXCR4 expression, enhanced cellular
proliferation, and colony formation, and suppressed apoptosis
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FIGURE 6 | Functional relevance of IGF2BP3/CXCR4 axis in EWS cells. (A) Western blotting displaying HIF-1α, IGF2BP3, and CXCR4 expression in
IGF2BP3-depleted or empty vector-transfected (shCTR) A673 EWS cells grown for 72 h under normoxia (21% O2) or hypoxia (1% O2). The western blots represent
the sum of three independent experiments. GAPDH was used as the loading control. (B) Migration of IGF2BP3-depleted or empty vector-transfected (shCTR) A673
EWS cells using a CXCL12 (100 ng/ml) gradient under normoxia (21% O2) or hypoxia (1% O2). Mean ± SE of three independent experiments is shown. **p < 0.01;
****p < 0.0001, one-way ANOVA.
(38). Clinicopathological correlation analysis additionally
indicated that CD164 upregulation was significantly associated
with tumor grade and metastasis. In EWS, a putative role for
CD164 in EWS transformation was suggested by Grunewald
et al. who demonstrated that the thyroid receptor interacting
protein 6 (TRIP6), belonging to the Zyxin family of proteins, is
overexpressed in EWS and promotes cell growth, invasion, and
migration through a transcriptional pro-invasive gene signature,
which included CD164 (42). However, CD164 mechanisms of
action in EWS cells were not further characterized and its impact
on tumor progression has never been evaluated.
According to previous evidences (33, 34), our data confirm
a direct functional interaction between IGF2BP3 and CD164.
In fact, IGF2BP3 and CD164 are part of a complex detected
by RIP assays, suggesting that IGF2BP3 might regulate mRNA
stability and therefore expression levels of CD164. In turn,
CD164 functionally interacts with CXCR4, thus regulating
CXCR4 activation and CXCL12-dependent motility of EWS cells.
In ovarian cancer cells, CD164 was localized in the cytosol
and nucleus suggesting that nuclear CD164 might regulate
CXCR4 promoter activity (38). The definition of downstream
mechanisms of action of this signaling axis in EWS cells
deserves further studies. It is important to mention that, in
addition to IGF2BP3, additional proteins may contribute to
CD164/CXCR4 regulation at post-transcriptional or epigenetic
level, as suggested by the moderate associations between these
3 molecules observed in EWS cases. For instance, CXCR4 is
regulated by dynamic post-translational histone modifications
(15) while CD164 is a direct target of miRNA124, whose role
in EWS has been previously reported (43, 44). Here, we put
emphasis on the definition of an axis that may favor metastasis
formation, the critical medical issue in the cure of EWS patients,
and we provide evidence that support the possible use of
drugs targeting IGF2BP3 and/or CXCR4 in high-risk patients
with high expression of IGF2BP3/CD164/CXCR4 molecules. As
recently reported, CXCL12 favors a pro-metastatic bone marrow
niche in multiple myeloma, as well as in solid tumors with
propensity to give bone metastases, including gastric, medullary
thyroid, lung, prostate, and renal carcinomas (45). CXCR4-
blocking agents, such as the neutralizing antibody MDX1338
or Ulocuplumab, were reported to efficiently reduce migration
and invasion of osteosarcoma, alveolar rhabdomyosarcoma and
myeloma cells and suppress the CXCR4-driven Epithelial-to-
mesenchymal (EMT)-like phenotype (45–47), supporting the
specific targeting of CXCR4 in therapy. More recently, the
combination of MDX1338 and activated and expanded natural
killer (NKAE) cell therapy was proposed as novel therapeutic
approach to efficiently inhibit metastasis in mice (48). However,
considering that CXCR4 may be up-regulated by epigenetic
alterations or hypoxia-driven signaling which allow tumor
cells to adapt and win the selection leading to tumor cell
dissemination and metastasis in a new host environment,
inhibition of IGF2BP3 may be more relevant. We have recently
reported that inhibitors of Bromodomain and Extraterminal
domain (BET) proteins can reduce expression of IGF2BP3
in EWS cells and synergize with vincristine (21). Further
studies are necessary to develop more specific agents against
this oncogenetic RBP.
In summary, the data presented in this work identified
CD164 and CXCR4 as novel IGF2BP3 downstream functional
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effectors supporting the notion that the IGF2BP3/CD164/CXCR4
oncogenic axis may work as critical modulator of EWS
aggressiveness. In addition, IGF2BP3, CD164, and CXCR4
expression levels may work as novel biomarkers predictive of
EWS progression. Targeting of this axis may effectively prevent
EWS disease dissemination.
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